查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790226

帕金森氏症血液生物标记市场规模、份额和趋势分析报告：按生物标记、技术、最终用途、地区和细分市场预测，2025-2033 年

Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

帕金森氏症血液生物标记市场概述

2024 年，帕金森氏症血液生物标记的全球市场规模估计为 1.1779 亿美元，预计到 2033 年将达到 3.5087 亿美元，2025 年至 2033 年的复合年增长率为 19.25%。由于全球帕金森氏症患者病率上升、神经诊断和生物标记研究投入增加以及蛋白质组学和基因组学技术的进步等因素，市场正在经历显着增长。

根据 2021 年全球疾病负担调查的数据，研究人员预测，到 2050 年，全球将有约 2,520 万人患有帕金森氏症，无论年龄或性别，与 2021 年记录的数字相比增长 112%。全球帕金森氏症 (PD) 在老年人中的盛行率呈上升趋势，尤其是在北美、欧洲和亚太部分地区。 PD 的盛行率随着老龄化的增长而显着增加，老龄化是该疾病的主要危险因素，尤其是对于 65 岁及以上的人。多项研究一致表明，在所有年龄层中，男性比女性更容易患有 PD。 PD 盛行率的增加与全球人口老化密切相关，这表明人口结构变化将在未来几十年继续增加患者数量。随着预期寿命的增加，PD 的负担预计会增加。 IHME 全球疾病负担（2024 年）显示了各大洲的 PD 病例。

患者数量的不断增长迫切需要早期、准确且微创的诊断工具。血液生物标记为传统临床和影像诊断提供了相当前景的替代方案。随着全球对神经退化性疾病的认识不断提高，对便捷诊断的需求也日益增长，这使得血液生物标记成为应对帕金森氏症日益加重的负担并支持早期治疗性介入的关键解决方案。

目录

第一章调查方法与范围

第二章执行摘要

第三章：帕金森氏症血液生物标记市场的趋势和展望

  • 市场体系展望
    • 母市场
    • 子公司市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 帕金森氏症血液生物标记市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
    • 法律规范
    • 定价分析
    • 赎回情景
    • 技术进步

第四章帕金森氏症市场中的血液生物标记：生物标记的估计和趋势分析

  • 细分仪表板
  • 帕金森氏症血液生物标记市场：生物标记变异分析
  • 帕金森氏症血液生物标记市场规模及趋势分析（按生物标记，2021-2033 年）
  • 蛋白质生物标记
  • 发炎标记物
  • 代谢标记物
  • 转录组学/miRNA
  • 其他的

5. 帕金森氏症血液生物标记市场（按动物类型划分）、估值和趋势分析

  • 细分仪表板
  • 帕金森氏症血液生物标记市场：动物类型变异分析
  • 帕金森氏症血液生物标记市场规模及趋势分析（依动物类型，2021-2033）
  • 狗
  • 猫
  • 马
  • 其他的

6. 帕金森氏症血液生物标记市场（按技术、估值和趋势分析）

  • 细分仪表板
  • 帕金森氏症血液生物标记市场：技术波动分析
  • 帕金森氏症血液生物标记市场规模及趋势分析（依技术划分）（2021-2033）
  • ELISA/免疫检测
  • 復用平台
  • NGS/qPCR（遗传学）
  • 质谱法
  • 其他的

7. 帕金森氏症血液生物标记市场（按最终用途、估值和趋势分析）

  • 细分仪表板
  • 帕金森氏症血液生物标记市场：最终用途变异分析
  • 帕金森氏症血液生物标记市场规模及趋势分析（按最终用途），2021-2033 年
    • 学术实验室
    • 製药/生物技术
    • 医院
    • 临床诊断实验室
    • 其他的

8. 帕金森氏症血液生物标记市场：区域、估值和趋势分析

  • 区域仪表板
  • 2024 年及 2033 年帕金森氏症血液生物标记市场占有率
  • 区域展望
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 市场参与企业分类
  • 企业市场分析/堆图分析
  • 公司简介
    • IDEXX Laboratories, Inc.
    • Abbott Laboratories
    • ACOBIOM
    • Alseres Pharmaceuticals
    • Banyan Biomarkers
    • Bio-Rad Laboratories
    • DiaGenic ASA
    • Johnson & Johnson
    • Merck KGaA
    • QIAGEN
  • 战略地图
    • 合併与收购
    • 伙伴关係和合作
    • 产品发布
    • 其他的
  • 其他主要参与企业名单
Product Code: GVR-4-68040-667-9

Blood-based Biomarker For Parkinson's Disease Market Summary

The global blood-based biomarker for Parkinson's disease market size was estimated at USD 117.79 million in 2024 and is projected to reach USD 350.87 million by 2033, growing at a CAGR of 19.25% from 2025 to 2033. The market is exhibiting significant growth driven by rising prevalence of Parkinson's disease worldwide, increasing investment in neurology diagnostics and biomarker research and advances in proteomics and genomic technologies.

The data from the global burden of disease study 2021, researchers project that by 2050, Parkinson's disease will affect approximately 25.2 million people worldwide across all ages and sexes, an increase of 112% compared to the numbers recorded in 2021. The global incidence of Parkinson's disease (PD) is increasing due to geriatric populations, particularly in North America, Europe, and parts of Asia-Pacific. Parkinson's disease (PD) incidence rates increase significantly with age, particularly among individuals aged 65 and older, making age the primary risk factor for the condition. Some studies consistently show that PD is more prevalent in males than females across all age groups. The rising incidence of PD closely correlates with the expanding aging population worldwide, suggesting that demographic shifts will continue to drive up the number of cases in the coming decades. As life expectancy increases, the burden of Parkinson's disease is expected to grow. The graph below depicts cases of Parkinson's disease in various continents according to the IHME Global Burden of Disease (2024):

This growing patient pool drives urgent demand for early, accurate and minimally invasive diagnostic tools. Blood-based biomarkers offer a promising alternative to traditional clinical and imaging-based diagnosis, which often detects PD only in later stages. As awareness of neurodegenerative diseases increases globally, so does the need for accessible diagnostics, positioning blood-based biomarkers as a critical solution to meet the rising burden of Parkinson's and support earlier therapeutic intervention.

Blood-based Biomarker For Parkinson's Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the blood-based biomarker for Parkinson's disease market report based on technology, biomarker, end use, and region:

  • Biomarker Outlook (Revenue, USD Million, 2021-2033)
  • Protein biomarkers
  • Inflammatory markers
  • Metabolic markers
  • Transcriptomic/miRNA
  • Others
  • Technology Outlook (Revenue, USD Million, 2021-2033)
  • ELISA/Immunoassay
  • Multiplex platforms
  • NGS/qPCR (genetic)
  • Mass spectrometry
  • Others
  • End Use Outlook (Revenue, USD Million, 2021-2033)
  • Academic/Research Labs
  • Pharmaceutical / Biotech (for Clinical Trials)
  • Hospitals
  • Clinical Diagnostic Labs
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Parkinson's Disease Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of Parkinson's disease worldwide
      • 3.2.1.2. Increasing investment in neurology diagnostics and biomarker research
      • 3.2.1.3. Advances in proteomics and genomic technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Costs and Technical Complexity Restrict Accessibility in Low-Resource Settings
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Blood-based Biomarker For Parkinson's Disease Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Reimbursement Scenario
    • 3.3.6. Technological Advancements

Chapter 4. Blood-based Biomarker for Parkinson's Disease Market: Biomarker Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Blood-based Biomarker For Parkinson's Disease Market: Biomarker Movement Analysis
  • 4.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by Biomarker, 2021 to 2033 (USD Million)
  • 4.4. Protein biomarkers
    • 4.4.1. Protein biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Inflammatory markers
    • 4.5.1. Inflammatory markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Metabolic markers
    • 4.6.1. Metabolic markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Transcriptomic/miRNA
    • 4.7.1. Transcriptomic/miRNA Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Blood-based Biomarker For Parkinson's Disease Market: Animal Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Blood-based Biomarker For Parkinson's Disease Market: Animal type Movement Analysis
  • 5.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by animal type, 2021 to 2033 (USD Million)
  • 5.4. Dogs
    • 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cats
    • 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Horses
    • 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Blood-based Biomarker for Parkinson's Disease Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Blood-based Biomarker for Parkinson's Disease Market: Technology Movement Analysis
  • 6.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 6.4. ELISA/Immunoassay
    • 6.4.1. ELISA/Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Multiplex platforms
    • 6.5.1. Multiplex platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. NGS/qPCR (genetic)
    • 6.6.1. NGS/qPCR (genetic) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Mass spectrometry
    • 6.7.1. Mass spectrometry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Blood-based Biomarker for Parkinson's Disease Market: By End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Blood-based Biomarker for Parkinson's Disease Market: By End Use Movement Analysis
  • 7.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 7.3.1. Academic/Research Labs
      • 7.3.1.1. Academic/Research Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Pharmaceutical / Biotech
      • 7.3.2.1. Pharmaceutical / Biotech Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Hospitals
      • 7.3.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Clinical Diagnostic Labs
      • 7.3.4.1. Clinical Diagnostic Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Others
      • 7.3.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Blood-based Biomarker for Parkinson's Disease Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Blood-based Biomarker for Parkinson's Disease Market Share, By Region, 2024 & 2033 (USD Million)
  • 8.3. Regional Outlook
  • 8.4. North America
    • 8.4.1. North America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. U.S. Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Canada Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Mexico Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. UK Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Germany Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. France Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Italy Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Spain Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory framework/ reimbursement structure
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Denmark Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory framework/ reimbursement structure
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Sweden Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory framework/ reimbursement structure
      • 8.5.9.3. Competitive scenario
      • 8.5.9.4. Norway Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Japan Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. China Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. India Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Australia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. South Korea Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Thailand Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Brazil Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Argentina Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East & Africa
    • 8.8.1. Middle East & Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. South Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory framework/ reimbursement structure
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. UAE Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory framework/ reimbursement structure
      • 8.8.5.3. Competitive scenario
      • 8.8.5.4. Kuwait Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. IDEXX Laboratories, Inc.
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Abbott Laboratories
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. ACOBIOM
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Alseres Pharmaceuticals
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Banyan Biomarkers
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. DiaGenic ASA
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Johnson & Johnson
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Merck KGaA
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. QIAGEN
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
      • 9.3.10.5. Quanterix
      • 9.3.10.6. Participant's Overview
      • 9.3.10.7. Financial Performance
      • 9.3.10.8. Product Benchmarking
      • 9.3.10.9. Strategic Initiatives
      • 9.3.10.10. Thermo Fisher Scientific
      • 9.3.10.11. Participant's Overview
      • 9.3.10.12. Financial Performance
      • 9.3.10.13. Product Benchmarking
      • 9.3.10.14. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Product launch
    • 9.4.4. Others
  • 9.5. List of other key players

List of tables

  • Table 1 List of secondary sources
  • Table 2 Blood-based Biomarker For Parkinson's Disease Market, by region, 2021 - 2033 (USD Million)
  • Table 3 Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 4 Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 5 Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 North America Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 8 North America Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 9 North America Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 10 U.S. Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 11 U.S. Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 12 U.S. Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 13 Canada Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 14 Canada Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 15 Canada Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Mexico Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 17 Mexico Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 18 Mexico Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Europe Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 20 Europe Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 21 Europe Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 22 Europe Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 23 Germany Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 24 Germany Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 25 Germany Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 27 UK Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 28 UK Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 29 France Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 30 France Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 31 France Blood-based Biomarker For Parkinson's Disease Market, by Type, 2021 - 2033 (USD Million)
  • Table 32 Italy Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 33 Italy Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 34 Italy Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 35 Spain Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 36 Spain Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 37 Spain Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Denmark Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 39 Denmark Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 40 Sweden Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 41 Sweden Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 42 Sweden Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 43 Norway Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 44 Norway Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 45 Norway Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 50 China Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 51 China Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 52 China Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 53 Japan Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 54 Japan Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 55 Japan Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 56 India Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 57 India Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 58 India Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 59 South Korea Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 60 South Korea Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 61 South Korea Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 62 Australia Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 63 Australia Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 64 Australia Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 65 Thailand Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 66 Thailand Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 67 Thailand Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 68 Latin America Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 69 Latin America Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 70 Latin America Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 71 Latin America Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 72 Brazil Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 73 Brazil Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 74 Brazil Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 75 Argentina Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 76 Argentina Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 77 Argentina Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 78 MEA Blood-based Biomarker For Parkinson's Disease Market, by country, 2021 - 2033 (USD Million)
  • Table 79 MEA Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 80 MEA Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 81 MEA Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 82 South Africa Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 83 South Africa Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 84 South Africa Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 88 UAE Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 89 UAE Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 90 UAE Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 92 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by Technology, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Blood-based Biomarker For Parkinson's Disease Market, by End Use, 2021 - 2033 (USD Million)
  • Table 94 Company Overview
  • Table 95 Product Benchmarking
  • Table 96 Financial Performance
  • Table 97 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Blood-based Biomarker For Parkinson's Disease Market revenue, 2021-2033 (USD Million)
  • Fig. 10 Blood-based Biomarker For Parkinson's Disease Market snapshot
  • Fig. 11 Blood-based Biomarker For Parkinson's Disease Market driver impact
  • Fig. 12 Blood-based Biomarker For Parkinson's Disease Market restraint impact
  • Fig. 13 Blood-based Biomarker For Parkinson's Disease biomarker key takeaways (USD Million)
  • Fig. 14 Blood-based Biomarker For Parkinson's Disease Market: biomarker movement analysis
  • Fig. 15 Protein biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 16 Inflammatory markers market, 2021 - 2033 (USD Million)
  • Fig. 17 Metabolic markers market, 2021 - 2033 (USD Million)
  • Fig. 18 Transcriptomic/miRNA market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Blood-based Biomarker For Parkinson's Disease technology key takeaways (USD Million)
  • Fig. 21 Blood-based Biomarker For Parkinson's Disease Market: technology movement analysis
  • Fig. 22 ELISA/Immunoassay market, 2021 - 2033 (USD Million)
  • Fig. 23 Multiplex platforms market, 2021 - 2033 (USD Million)
  • Fig. 24 NGS/qPCR (genetic) market, 2021 - 2033 (USD Million)
  • Fig. 25 Mass spectrometry market, 2021 - 2033 (USD Million)
  • Fig. 26 Others market, 2021 - 2033 (USD Million)
  • Fig. 27 Blood-based Biomarker For Parkinson's Disease Market by End Use key takeaways (USD Million)
  • Fig. 28 Blood-based Biomarker For Parkinson's Disease Market: by End Use movement analysis
  • Fig. 29 Academic/Research Labs market, 2021 - 2033 (USD Million)
  • Fig. 30 Pharmaceutical /Biotech market, 2021 - 2033 (USD Million)
  • Fig. 31 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 32 Clinical Diagnostic Labs market, 2021 - 2033 (USD Million)
  • Fig. 33 Others market, 2021 - 2033 (USD Million)
  • Fig. 34 Regional market place: Key takeaways
  • Fig. 35 Regional outlook, 2024 & 2033
  • Fig. 36 North America Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 39 Mexico Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 40 Europe Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 41 UK Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 43 France Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 45 Spain Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 51 China Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 52 India Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 53 Australia Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 54 South Korea Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 55 Thailand Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 56 Latin America Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 57 Brazil Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 58 Argentina Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 59 MEA Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 60 South Africa Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 61 Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 62 UAE Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 63 Kuwait Blood-based Biomarker For Parkinson's Disease Market, 2021 - 2033 (USD Million)
  • Fig. 64 Market participant categorization